Skip to main content

Advertisement

Table 1 Baseline characteristics

From: Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates

Baseline characteristic Naïve group (n = 25) Switch group (n = 11) P
Age (years) 66.2 ± 1.6 75.4 ± 2.2 <0.05
Height (cm) 150.4 ± 1.5 145.4 ± 2.5 n.s
Weight (kg) 45.7 ± 1.6 43.0 ± 1.9 n.s
Spine BMD (g/cm2) 0.824 ± 0.03 0.889 ± 0.06 n.s
FN BMD (g/cm2) 0.60 ± 0.01 0.57 ± 0.03 n.s
TH BMD (g/cm2) 0.62 ± 0.01 0.62 ± 0.03 n.s
Total-PINP (ng/ml) 73.4 ± 5.5 36.8 ± 5.1 n.s
TRACP-5b (mU/dl) 426.2 ± 31.3 320.7 ± 21.0 <0.05
ucOC (ng/ml) 4.2 ± 0.5 2.3 ± 0.4 <0.05
BPs duration (years) 7.9 ± 0.4
BPs used Alen 3, Ris 8
Previous fractures (%) a 28.0 81.8 <0.05
  1. Naïve group: treatment-naïve group; Switch group: transitioning from bisphosphonate group; BMD: bone mineral density; FN: femoral neck; TH: total hip; total-PINP: total-procollagen type I N-terminal propeptide; TRACP-5b: tartrate-resistant acid phosphatase-5b; ucOC: undercarboxylated osteocalcin; BPs: bisphosphonates; Alen: alendronate; Ris: risedronate
  2. aDefined as osteoporotic vertebral or nonvertebral fractures; assessment of vertebral fractures was performed for this study at baseline
  3. Data are presented as means ± standard deviation (SD). P values from Mann-Whitney U tests for continuous variables and Chi-squared tests for dichotomous variables